Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Expected to Post Earnings of -$0.22 Per Share

Brokerages expect Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Rating) (TSE:AUP) to announce ($0.22) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Aurinia Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.25) and the highest is ($0.19). Aurinia Pharmaceuticals reported earnings per share of ($0.37) in the same quarter last year, which suggests a positive year over year growth rate of 40.5%. The company is expected to report its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Aurinia Pharmaceuticals will report full year earnings of ($0.70) per share for the current fiscal year, with EPS estimates ranging from ($0.90) to ($0.48). For the next year, analysts forecast that the company will report earnings of ($0.07) per share, with EPS estimates ranging from ($0.40) to $0.23. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Rating) (TSE:AUP) last released its quarterly earnings data on Tuesday, May 10th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.27). Aurinia Pharmaceuticals had a negative return on equity of 43.20% and a negative net margin of 253.66%. During the same period in the previous year, the firm posted ($0.40) EPS.

A number of equities research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, May 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Aurinia Pharmaceuticals in a research note on Thursday, April 28th. HC Wainwright decreased their target price on shares of Aurinia Pharmaceuticals from $33.00 to $30.00 in a research note on Wednesday, May 4th. Royal Bank of Canada decreased their target price on shares of Aurinia Pharmaceuticals from $27.00 to $22.00 and set an “outperform” rating for the company in a research note on Thursday, April 28th. Finally, StockNews.com started coverage on Aurinia Pharmaceuticals in a research note on Thursday, March 31st. They issued a “sell” rating for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Aurinia Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $25.60.

AUPH stock traded down $0.08 during midday trading on Monday, hitting $11.97. The company’s stock had a trading volume of 110,160 shares, compared to its average volume of 2,888,102. The company has a market cap of $1.70 billion, a PE ratio of -9.32 and a beta of 1.09. Aurinia Pharmaceuticals has a 12 month low of $8.86 and a 12 month high of $33.97. The firm’s 50-day moving average is $11.48 and its 200-day moving average is $16.59.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. International Biotechnology Trust PLC increased its position in shares of Aurinia Pharmaceuticals by 30.0% during the first quarter. International Biotechnology Trust PLC now owns 435,000 shares of the biotechnology company’s stock worth $3,955,000 after acquiring an additional 100,500 shares during the period. BNP Paribas Arbitrage SA increased its position in shares of Aurinia Pharmaceuticals by 54,590.3% during the first quarter. BNP Paribas Arbitrage SA now owns 56,331 shares of the biotechnology company’s stock worth $697,000 after acquiring an additional 56,228 shares during the period. Gabelli Funds LLC increased its position in shares of Aurinia Pharmaceuticals by 8.3% during the first quarter. Gabelli Funds LLC now owns 390,000 shares of the biotechnology company’s stock worth $4,828,000 after acquiring an additional 30,000 shares during the period. Walleye Capital LLC purchased a new position in shares of Aurinia Pharmaceuticals during the first quarter worth approximately $428,000. Finally, Virtu Financial LLC purchased a new position in shares of Aurinia Pharmaceuticals during the first quarter worth approximately $246,000. 33.09% of the stock is owned by institutional investors and hedge funds.

About Aurinia Pharmaceuticals (Get Rating)

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.

See Also